Purpose of review Autosomal recessive hypercholesterolemia (ARH) is a rare Mendelian dyslipidemia characterized by markedly elevated plasma LDL levels, xanthomatosis, and premature coronary artery disease. LDL receptor function is normal, or only moderately impaired in fibroblasts from ARH patients, but their cultured lymphocytes show increased cell-surface LDL binding, and impaired LDL degradation, consistent with a defect in LDL receptor internalization. Recently, the disorder was shown to be caused by mutations in a phosphotyrosine binding domain protein, ARH, which is required for internalization of low density lipoproteins in the liver. This review summarizes the findings of new investigations into the pathophysiology and molecular genetics of ARH.
Introduction
In 1973, Khachadurian and Uthman [1] described an unusual Lebanese family in which all four offspring had the clinical features of homozygous familial hypercholesterolemia, a dominantly inherited disease, and yet both parents had normal plasma cholesterol levels. The children all had hypercholesterolemia (mean plasma cholesterol level of 728 mg/dl) and huge tendon xanthomas. Subsequently, other patients with a recessive form of severe hypercholesterolemia were described [2] [3] [4] [5] , including five unrelated probands from Sardinia [2, 3] . This new disorder was named autosomal recessive hypercholesterolemia (ARH).
Familial hypercholesterolemia is caused by mutations in the LDL receptor (LDLR), the major conduit for entry of LDL into cells [6] . The predominant site of LDL clearance is the liver. Patients with homozygous familial hypercholesterolemia have essentially no LDLR activity, resulting in a marked retardation in the rate of LDL clearance [6] ; cultured fibroblasts from these patients also fail to internalize LDL [6] . Patients with ARH clear LDL from the circulation as slowly as do patients with familial hypercholesterolemia, suggesting they share a defect in hepatic LDLR function. In contrast to patients with homozygous familial hypercholesterolemia, however, cultured fibroblasts from patients with ARH have almost normal LDL uptake [2] .
Norman and colleagues [7] identified two consanguineous families with a recessive form of severe hypercholesterolemia that did not segregate with the LDLR gene. Transformed lymphocytes from these patients failed to internalize LDL but internalized transferrin normally, indicating that the cells did not have a generalized defect in receptor mediated endocytosis. The disease was mapped in these two families to the short arm of chromosome 1 (1p36) [8] .
Identification of the gene defective in autosomal recessive hypercholesterolemia
The gene defect in ARH was identified by linkage mapping in two Sardinian and two Lebanese families with the condition [9] . All probands were offspring of first cousin matings and had severe hypercholesterolemia (plasma LDL cholesterol levels between 400 and 600 mg/dl) with normal plasma levels of triglyceride and HDL cholesterol. The affected family members had large, bulky xanthomas and many also had xanthelasmas.
The probands had premature onset of coronary artery disease, with clinical manifestations (exertional angina) beginning at age 23 in one of the affected men and subclinical coronary artery disease documented by angiogram in his 20-year-old sister. Some probands also had aortic stenosis, as occurs in homozygous familial hypercholesterolemia. LDLR function in cultured fibroblasts was greater than 50% of normal in all probands (Table 1) .
Multipoint mapping in the four families localized the defective gene to a 5.7 cM interval on the short arm of chromosome 1 (1p34-1p35). DNA sequencing of candidate genes within the linked region revealed homozygosity for mutations in a previously uncharacterized EST (DKFZp586D0624) [9] . The gene corresponding to this EST, designated ARH, spans around 20 kb, and has nine exons and eight introns (Fig. 1) . Sequencing of the ARH gene from the probands of these families revealed four different mutations.
Molecular genetics of autosomal recessive hypercholesterolemia
To date, eight mutations in ARH have been described in patients with recessive hypercholesterolemia [10] (Fig. 1) . We initially identified six ARH mutations in patients from Lebanon, Sardinia, Iran, Italy, and the United States [9] . Five of these mutations introduced premature termination codons. A proline to histidine substitution in codon 202 was the only mutation identified in the coding region of one of the Lebanese patients; this mutation was initially thought to be the disease-causing mutation since it was not present in 40 ARH alleles from normolipidemic Lebanese individuals. Subsequent studies [10] revealed a nucleotide substitution in intron 7 creating a splice donor site and introducing an additional exon. The new exon results in the formation of a premature termination codon downstream of exon 7. None of these mutations are associated with full length protein.
The two remaining ARH mutations that have been described also interfere with the production of fulllength ARH. Al-Kateb et al. [11] identified a G to C mutation in the splice acceptor sequence of exon 1 in three Syrian siblings with ARH. More recently, we identified a patient with no immunodetectable protein who was homozygous for an insertion of a composite retroposon referred to as a SVA (sine VNTR Alu) [12] in intron 1 of an ARH allele (ARH7). Bi-directional sequencing of the entire ARH gene in ARH7 revealed no other alterations. The mechanism by which the SVA insert interferes with ARH expression is not known.
Although transcripts containing premature termination codons are usually targeted for rapid degradation through the process known as mRNA decay [13] , ARH mRNA levels were normal in cells from two individuals (ARH2 and ARH6) with premature termination codons [10] . The mechanism by which these transcripts evade nonsense-mediated decay is not known. Studies of nonsense mutations in other proteins have demonstrated that nonsense-mediated mRNA decay requires at least one exon 3' of the premature termination codon, and a minimum interval of 50-55 bp between the nonsense codon and the last intron-exon boundary [13] . In the HLA-A gene, mutations that introduce premature termination codons in exons 6 and 7 fail to trigger nonsense mediated decay due to the unusually small sizes of these exons (33 and 48 nt, respectively) [14] . However, neither the location of the mutation nor the size of the exon containing the premature termination codons account for the preservation of transcripts from ARH2 and ARH6. The mutations in these alleles both introduce premature termination codons towards the 5' end of the transcript (in exons 1 and 2, respectively), and both exons are longer than 55 basepairs, the minimum footprint required for detection by the surveillance machinery. An alternative explanation for the normal mRNA levels in ARH2 and ARH6 is that translation may initiate after the premature stop codon either through leaky scanning or by reinitiation of translation, which abrogates nonsense-mediated mRNA decay in mammalian cells [15] . Small amounts of an *32 kDa protein were detected in the lymphoblasts from ARH2, suggesting that translation may initiate from one of two downstream AUG codons (M46 and M55) that are in-frame and in an adequate context for initiation [16] . 
Population genetics of autosomal recessive hypercholesterolemia
Almost all of the approximately 50 ARH individuals identified to date are of Mediterranean or Middle Eastern origin, and more than half are from the island of Sardinia. The high frequency of ARH in Sardinia is likely to be caused by a combination of genetic drift, consanguinity, and geographic isolation. Two mutations, FS170Stop (ARH1) and W22Stop (ARH2), account for all known cases of ARH on Sardinia [17] . Both mutations are diffusely distributed on the island, suggesting that they were introduced by early settlers, rather than by more recent immigrants to the island. The estimated ages of ARH1 and ARH2 are consistent with this view. We estimated the ages of ARH1 and ARH2 using the model of Serre et al. [18] (see also [19] for detailed discussion) of linkage disequilibrium dissolved by the recombination process. We fitted the model of Serre et al. [18] to data on 30 polymorphic sites in the 670 kb interval, containing the ARH gene, between D1S167 and D1S2885. Using the least squares procedure, we obtained estimates of the age of the ARH1 mutation equal to 289 generations (with 95% confidence interval 201-377 generations) and of the age of the ARH2 mutation equal to 217 generations (with 95% confidence interval 83-352 generations).
Remarkably, a third allele identified in a minority of Sardinian ARH patients includes both the W22Stop and In (A) mutations ARH1-ARH7 are described in Refs [9, 10] . The mutation IVS1-1G4C is from Ref. [11] . Bars represent exons, lines denote introns. In (B) grey boxes indicate amino acids that are identical in all four species. The four conserved domains include the N-terminus (broken line), the phosphotyrosine-binding domain (solid line), the clathrin box (double underline), and the b-adaptin binding domain (dotted line).
the FS170Stop mutations [17] . The haplotype of this allele shares common elements with both the ARH1 and ARH2 alleles, indicating that it arose by recombination between the ARH1 and ARH2 alleles. The limited extent of the sequence shared in common with ARH1 and ARH2, however, suggests that the recombination event did not occur recently.
The high proportion (65%) of unrelated ARH probands homozygous for mutant alleles suggests that either these mutations are common or that consanguinity is frequent on Sardinia. Inbreeding was present in two of the families that we studied, and previous estimates suggest that about 10% of marriages on Sardinia between 1910 and 1969 were consanguineous. Genetic drift due to geographic isolation, coupled with the historically high rates of consanguinity, most likely contributes to the high rate of allelic homozygosity in the ARH probands.
Zlotogora [20] suggested that consanguinity or isolation would be expected to lead to the presence of one major founder mutation. The existence of multiple ARH mutations on Sardinia may indicate that carriers have a selective advantage.
Clinical characteristics of autosomal recessive hypercholesterolemia
Clinical characterization of 28 Sardinians and four Italians with ARH indicated that the mean plasma levels of LDL cholesterol are lower in these patients (548 mg/ dl) than in Italian patients with homozygous familial hypercholesterolemia (679 mg/dl) [17] . These levels are intermediate between those of familial hypercholesterolemia heterozygotes and familial hypercholesterolemia homozygotes. Approximately half of the 32 ARH patients had evidence of coronary artery disease at the time of diagnosis and six had symptomatic disease before age 40. The onset of clinically significant coronary artery disease tends to be later in ARH patients than in patients with homozygous familial hypercholesterolemia, presumably due to the lower levels of plasma cholesterol.
Despite the tendency toward lower plasma levels of cholesterol relative to familial hypercholesterolemia homozygotes, patients with ARH often have large, bulky xanthomas (one affected Sardinian patient complained that the xanthomas on his knees were so large he could not rest his child on his lap). The reason for the large size of the xanthomas in ARH patients is not known. The LDLR is not thought to play a direct role in the formation of cholesterol-rich foam cells since it is expressed at very low levels in cholesterol-loaded macrophages [6] . Maintenance of LDLR activity in the macrophages of patients with ARH may promote increased uptake and accumulation of cholesterol in these cells, resulting in accelerated xanthoma formation.
Mice engrafted with LDLR-deficient bone marrow had reduced lipid accumulation in the aorta despite having increased plasma levels of cholesterol [21] , which is consistent with LDLR expression in macrophages promoting cholesterol accumulation in macrophages.
Patients with ARH appear to respond to lipid-lowering medications with more substantial plasma cholesterol reductions than patients with homozygous familial hypercholesterolemia. In familial hypercholesterolemia homozygotes, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors lead to modest reductions in plasma cholesterol levels, even when administered at high doses [22] . In contrast, these agents produce striking reductions in plasma cholesterol in some ARH patients [17] . The increased level of expression of the LDLR associated with statins [23] may compensate to some degree for the defective hepatic LDLR function in ARH. Most ARH patients do not reach optimal plasma cholesterol levels on lipid-lowering medications alone, and are maintained on LDL apheresis [17] .
Role of autosomal recessive hypercholesterolemia in LDL receptor function
The similar phenotypes of ARH and familial hypercholesterolemia suggest that the ARH protein plays a role in LDLR-mediated endocytosis. LDL turnover studies performed in two Sardinians with ARH provided direct evidence for defective LDL uptake in the livers of these individuals [2] . The clearance of LDL from the circulation was reduced by fourfold compared with normal individuals, and was similar to the rate observed in a familial hypercholesterolemia homozygote studied simultaneously [2] . The uptake of technecium labeled LDL from the circulation into the liver was negligible in the ARH patients. These studies indicate that ARH is required for the normal uptake of LDL into the liver. The specific role of ARH in LDLR function, however, has not been fully defined. Cultured skin fibroblasts, which provided critical insights into the molecular mechanisms underlying familial hypercholesterolemia [6] , do not recapitulate the defective LDLR function observed in ARH individuals. Whereas fibroblasts from patients with homozygous familial hypercholesterolemia take up radiolabeled LDL at less than 10% of the rate observed in fibroblasts from normal individuals [6] , fibroblasts from most ARH individuals take up and degrade LDL at 50-100% of the normal rate [17] . An elegant study by Norman et al. [7] indicated that LDLR function is defective in lymphocytes from two ARH patients. Pronase treatment of EBV-transformed lymphoblasts from these patients indicated that almost all of the LDLRs in these cells were on the plasma membrane and failed to internalize. FACS analysis using BODIPYlabeled LDL indicated increased cell-surface LDL binding, but markedly reduced LDL degradation in these cells. Accordingly, Norman et al. [7] proposed that the patients had a defect in a protein that was required for LDLR internalization. Similar results were obtained from ARH lymphocytes studied in our laboratory [10] . These data are consistent with the participation of ARH in the internalization of the LDLR-LDL complex.
The sequence of ARH is highly conserved between species, and alignment of the human sequence with homologs from mouse, frog and zebrafish revealed at least four blocks of highly conserved residues [24] (Fig.  1) . The N-terminal portion of the protein consists of a highly conserved *40 amino acid sequence that is not found in any other protein, followed by an *130 residue phosphotyrosine-binding (PTB) domain. A pentapeptide (LLDLE in the human sequence) referred to as a clathrin box consensus sequence [25] is encoded by residues 212-216. This sequence motif mediates the binding of several coated pit accessory proteins to the heavy chain of clathrin [25] .
To further define the function of ARH, we used pulldown experiments to test for interactions between ARH, the LDLR, and proteins involved in clathrin-mediated endocytosis [24] . The PTB domains of several proteins bind to peptides containing the motif NPXY, a canonical internalization sequence first identified in the LDLR. Although the first PTB domains to be characterized only bound the motif when the tyrosine residue was phosphorylated, several PTB domains including X11, Fe65, Dab, and Numb bind nonphosphorylated targets [26] . Pull-down experiments using recombinant proteins demonstrated that the PTB domain of ARH can interact with the LDLR tail in vitro, and that the integrity of the NPVY sequence is required for this interaction. Substitution of the tyrosine in the NPVY motif (Y807) with alanine or cysteine markedly reduced the interaction between ARH and the LDLR tail, whereas the introduction of phenylalanine at this position did not alter the interaction between the two proteins. These data suggested that the PTB domain of ARH binds to the LDLR cytoplasmic tail and that this binding requires an aromatic amino acid in the fourth position of the NPVY sequence.
Clathrin is a major structural component of the clathrincoated pit. The clathrin molecule comprises a trimer of 190 kDa heavy chain subunits and is shaped like a triskelion [27] . Each heavy chain has a C-terminal domain that is involved in trimerization, a proximal domain that controls lattice formation, a distal domain, and an N-terminal domain that binds to several adaptor proteins. The crystal structure of the N-terminal domain reveals a zig-zag linker attached to a b-propeller globular domain. Clathrin box sequences bind to residues in a cleft between the first two b-sheets of the aminoterminal b-propeller of the clathrin heavy chain [28] . This cleft contains two hydrophobic pockets: a small pocket that accommodates the side chain of the first leucine of the clathrin box, and a second, larger pocket that holds the side chains of the second and fourth hydrophobic residues [28] . R64 and K96 in the clathrin terminal domain interact with the fifth, acidic residue of the clathrin box [28] . Recombinant ARH bound to purified clathrin with high affinity (*44 K D ), and to a glutathione-S-transferase fusion protein containing the N-terminal 494 amino acids of the clathrin heavy chain. The clathrin box in ARH was required for clathrin binding: replacement of the first two leucine residues, or of the two acidic residues, with alanines abolished binding to the clathrin terminal domain. Thus ARH contains a functional clathrin box sequence that may participate in the recruitment or retention of LDLR to clathrin coated pits by ARH.
Several endocytic accessory proteins bind both clathrin and AP-2 [29] . Pull-down experiments indicate that ARH can interact with the b 2 -adaptin subunit of AP-2 [24] . The region of ARH required for binding to b 2 -adaptin is distinct from the LDLR and clathrin binding domains, and corresponds to the fourth highly conserved sequence motif that extends from residue 249 to residue 276 in the ARH protein. The interaction between ARH and b 2 -adaptin is highly specific: substitution of a single conserved arginine residue (R266) in ARH, or glutamic acid residue (E849) in b 2 -adaptin abolishes binding between the two proteins [24] .
Conclusions and unresolved issues
Eden et al. described three new ARH mutations including two frameshift mutations and one missense mutation (c.733C4T) that changed codon 238 from arginine to tryptophan. These authors were able to reconstitute LDL uptake in ARH lymphocytes by retroviral expression of ARH [33] . Taken together, the available data support the hypothesis that ARH functions as a modular adaptor protein that links the LDLR to the endocytic machinery of the coated pit. Further studies will be required to address three unresolved questions. First, it is not known if ARH is required to chaperone LDLRs to coated pits, or simply to anchor receptors in the pits during internalization (Fig. 2) . A naturally occurring mutation (Y807C) that prevents ARH from binding to the cytoplasmic tail also prevents LDLR from clustering in coated pits [24, 30] . This finding suggests that ARH plays a role in LDLR clustering, but direct observations of LDLR trafficking in ARH deficient cells will be required to confirm this. Second, it is not known why ARH is required for LDLR function in some cell types, such as hepatocytes, but not in fibroblasts. One possibility is that another adaptor protein fulfills the role of ARH in fibroblasts, but not in hepatocytes. Alternatively, the process of LDLR internalization may differ in hepatocytes and fibroblasts. For example, most LDLRs are clustered in coated pits in fibroblasts but appear to be dispersed on the plasma membrane in hepatocytes [31, 32] . Thus ARH may perform a specific function in hepatocytes that is not required in fibroblasts.
Finally, ARH appears to be a perfect phenocopy of homozygous familial hypercholesterolemia [17] , which is consistent with all clinical sequelae of ARH mutations being attributable to defective LDLR activity. ARH may be involved in other receptor pathways, but no other phenotypes that would indicate defective function of other NPXY-containing proteins have been reported in ARH patients. More detailed clinical phenotyping in ARH patients and in animal models will be required to explore the possibility of defects in other pathways. 
